Aminoglycoside toxicity in neonates: something to worry about?

References

• Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011;96(1):F4-8
   Google Scholar
• Turner MA, Lewis S, Hawcutt DB, Field D. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009;9:50
   PubMedGoogle Scholar
• National Institute of Health and Care Excellence. Antibiotics for Early Onset Neonatal Infection August 2012.
   Google Scholar
• Mims C, Playfair J, Roitt I, et al. Medical microbiology. 2nd edition. Mosby, Inc. London, UK; 1998. p. 419-22
   Google Scholar
• Quiros Y, Vicente-Vicente L, Morales AI, et al. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci 2011;119(2):245-56
   PubMed Web of Science ®Google Scholar
• Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 2009;65(4):419-27
   PubMedGoogle Scholar
• Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39(6):677-86
   PubMedGoogle Scholar
• Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012(2):CD002009
   Google Scholar
• Mavros MN, Polyzos KA, Rafailidis PI, Falagas ME. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66(2):251-9
   Google Scholar
• BNF for children. Available from: www.BNF.org [Last accessed 13 November 2013]
   Google Scholar
• Madsen L, Rasmussen M, Bjerregaard L, et al. Impact of blood sampling in very preterm infants. Scand J Clin Lab Invest 2000;60(2):125-32
   PubMed Web of Science ®Google Scholar
• Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):9-22
   PubMed Web of Science ®Google Scholar
• Contopoulos-Ioannidis DG, Giotis ND, Baliatsa D V, et al. Extended-interval aminoglycoside administration for children. Pediatrics 2004;114(1):e111-18
   Web of Science ®Google Scholar
• Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev 2011(3):CD008234
   Google Scholar
• Hawkins JE, Lurie MH. The ototoxicity of streptomycin. Trans Am Otol Soc 1952;40:133-53
   PubMedGoogle Scholar
• Heck WE, Hinshaw HC, Parsons HG. Auditory ototoxicity in tuberulous patients treated with a report of the incidence of hearing loss in a series of 1150 cases. JAMA 1963;186:18-20
   PubMedGoogle Scholar
• Jawetz E. Neomycin ototoxicity: dossier and dosage. N Engl J Med 1969;281(4):219
   PubMedGoogle Scholar
• McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med 1986;80(6B):172-8
   PubMedGoogle Scholar
• Brummett RE, Fox KE, Bendrick TW, Himes DL. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J Antimicrob Chemother 1978;4(Suppl A):73-83
   PubMedGoogle Scholar
• Dulon D, Aran JM, Zajic G, Schacht J. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986;30(1):96-100
   PubMed Web of Science ®Google Scholar
• Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin Blood Levels: a Guide to Nephrotoxicity. Antimicrob Agents Chemother 1975;3:202-15
   Google Scholar
• Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984;149(1):23-30
   PubMedGoogle Scholar
• Fee W. Aminoglycoside ototoxicity in the human. Larynogoscope 1980;90(Supp 24):1-9
   PubMedGoogle Scholar
• Black RE, Lau WK, Ralph J, et al. Ototoxicity of Amikacin. Antimicrob Agents Chemother 1976;9:956-61
   PubMed Web of Science ®Google Scholar
• Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007;13(1):119-26
   PubMed Web of Science ®Google Scholar
• Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007;72(8):931-5
   PubMed Web of Science ®Google Scholar
• Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103(2):239-52
   PubMed Web of Science ®Google Scholar
• Li H, Wang Q, Steyger PS. Acoustic trauma increases cochlear and hair cell uptake of gentamicin. PLoS One 2011;6(4):e19130
   PubMedGoogle Scholar
• Huth ME, Ricci A J, Cheng A G. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011;2011:937861
   PubMedGoogle Scholar
• Corbacella E, Lanzoni I, Ding D, et al. Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear Res 2004;197(1-2):11-18
   PubMed Web of Science ®Google Scholar
• Tran Ba Huy P, Manuel C, Meulemans A, et al. Pharmacokinetics of gentamicin in perilymph and endolymph of the rat as determined by radioimmunoassay. J Infect Dis 1981;143(3):476-86
   PubMedGoogle Scholar
• Assael B, Parini R, Rusconi F. Ototoxicity of aminoglycoside antibiotics in infants and children. Pediatr Infect Dis 1982;1(5):357-65
   PubMedGoogle Scholar
• Bernard P. Freedom from ototoxicity in aminoglycoside treated neonates: a mistaken notion. Laryngoscope 1981;91(12):1985-94
   PubMedGoogle Scholar
• Zorowka P, Schmitt HJ, Eckel HE, et al. Serial measurements of transient evoked otoacoustic emissions (TEOAEs) in healthy newborns and in newborns with perinatal infection. Int J Pediatr Otorhinolaryngol 1993;27(3):245-54
   PubMedGoogle Scholar
• Finitzo-Hieber T, Mccraeken GH, Brown KC. Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatrics 1985;106(1):129-36
   PubMedGoogle Scholar
• Jacobson J, Jacobson C. Evaluation of hearing loss in infants and young children. Pediatr Ann 2004;33(12):811-21
   PubMedGoogle Scholar
• Yoon PJ, Price M, Gallagher K, et al. The need for long-term audiologic follow-up of neonatal intensive care unit (NICU) graduates. Int J Pediatr Otorhinolaryngol 2003;67(4):353-7
   PubMedGoogle Scholar
• Village EG. Newborn and Infant Hearing Loss: detection and Intervention. Pediatrics 1999;103(2):527-30
   PubMedGoogle Scholar
• Vohr BR, Widen JE, Cone-Wesson B, et al. Identification of neonatal hearing impairment: characteristics of infants in the neonatal intensive care unit and well-baby nursery. Ear Hear 2000;21(5):373-82
   PubMedGoogle Scholar
• Halpern J, Hosford-Dunn H, Malachowski N. Four factors that accurately predict hearing loss in “high risk” neonates. Ear Hear 1987;8(1):21-5
   PubMedGoogle Scholar
• Cone-Wesson B, Vohr BR, Sininger YS, et al. Identification of neonatal hearing impairment: infants with hearing loss. Ear Hear 2000;21(5):488-507
   PubMed Web of Science ®Google Scholar
• Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for sensorineural hearing loss in NICU infants compared to normal hearing NICU controls. Int J Pediatr Otorhinolaryngol 2010;74(9):999-1002
   PubMed Web of Science ®Google Scholar
• De Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003;142(1):41-6
   PubMedGoogle Scholar
• Abramovich SJ, Gregory S, Slemick M, Stewart A. Hearing loss in very low birthweight infants treated with neonatal intensive care. Arch Dis Child 1979;54(6):421-6
   PubMedGoogle Scholar
• Stavroulaki P, Apostolopoulos N, Dinopoulou D, et al. Otoacoustic emissions–an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999;50(3):177-84
   PubMed Web of Science ®Google Scholar
• Kumana C, Yuen K. Parental aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47(6):902-13
   PubMed Web of Science ®Google Scholar
• Salamy A, Eldredge L, Tooley WH. Neonatal status and hearing loss in high-risk infants. J Pediatr 1989;114(5):847-52
   PubMedGoogle Scholar
• Lane A Z, Wright GE, Blair DC. Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States. Am J Med 1977;62(6):911-18
   PubMedGoogle Scholar
• Itsarayoungyuen S, Riff L, Schauf V, et al. Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function. Pediatric Pharmacol 1982;2(2):143-55
   PubMedGoogle Scholar
• De Hoog M, van Zanten GA, Hoeve LJ, et al. A pilot case control follow-up study on hearing in children treated with tobramycin in the newborn period. Int J Pediatr Otorhinolaryngol 2002;65(3):225-32
   PubMedGoogle Scholar
• Rao S, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates (Review). Cochrane Database Syst Rev 2011(1):CD005091
   Google Scholar
• Robertson CMT, Howarth TM, Bork DLR, Dinu I A. Permanent bilateral sensory and neural hearing loss of children after neonatal intensive care because of extreme prematurity: a thirty-year study. Pediatrics 2009;123(5):e797-807
   PubMedGoogle Scholar
• Brummett R. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis 1981;3:S216-23
   Google Scholar
• Brown JJ, Brummett RE, Meikle MB, Vernon J. Combined effects of noise and neomycin. Cochlear changes in the guinea pig. Acta Otolaryngologica 1978;86(5-6):394-400
   PubMed Web of Science ®Google Scholar
• Li H, Steyger P. Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics. Noise Health 2009;11(42):26-32
   PubMed Web of Science ®Google Scholar
• Lasky RE, Williams AL. Noise and light exposures for extremely low birth weight newborns during their stay in the neonatal intensive care unit. Pediatrics 2009;123(2):540-6
   PubMed Web of Science ®Google Scholar
• Fischel-Ghodsian N. Mitochondrial deafness mutations reviewed. Hum Mutat 1999;13(4):261-70
   PubMedGoogle Scholar
• Fischel-ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial predisposing gene mutation is a significant factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997;18(3):173-8
   PubMed Web of Science ®Google Scholar
• Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 2005;6(1):27-36
   PubMed Web of Science ®Google Scholar
• Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993;21(18):4174-9
   PubMedGoogle Scholar
• Hobbie SN, Akshay S, Kalapala SK, et al. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008;105(52):20888-93
   PubMed Web of Science ®Google Scholar
• Qian Y, Guan M-X. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 2009;53(11):4612-18
   PubMed Web of Science ®Google Scholar
• Arnos K, Xia X, Norris J. Relative frequencies of the mitochondrial A1555G and 961 delT mutations in the 12SrRNA gene from a large sample of deaf probands from the United States. Am Soc Hum Gen 2003;Abstract 2196
   Google Scholar
• Estivill X, Govea N, Barceló E, et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 1998;62(1):27-35
   PubMedGoogle Scholar
• Roland P. New developments in our understanding of ototoxicity. Ear Nose Throat J 2004;83(9 Suppl):15-16
   PubMedGoogle Scholar
• Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A–>G mutation in European children. N Engl J Med 2009;360(6):640-2
   PubMed Web of Science ®Google Scholar
• Ding Y, Leng J, Fan F, et al. The role of mitochondrial DNA mutations in hearing loss. Biochem Genet 2013;51(7-8):588-602
   PubMedGoogle Scholar
• Tang H, Hutcheson E, Neill S, Drummond-Borg M. Genetic susceptibility to aminoglycoside ototoxicity: How many are at risk? Genet Med 2002;4(5):336-45
   PubMedGoogle Scholar
• Casano R, Johnson D, Bykhovskaya Y, et al. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999;20(3):151-6
   PubMedGoogle Scholar
• Johnson RF, Cohen AP, Guo Y, et al. Genetic mutations and aminoglycoside-induced ototoxicity in neonates. Otolaryngol Head Neck Surg 2010;142(5):704-7
   PubMedGoogle Scholar
• Boyle EM, Brookes I, Nye K, et al. “Random” gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens. BMC Pediatr 2006;6:8
   PubMedGoogle Scholar
• Tomlinson RJ, Ronghe M, Goodbourne C, et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child 1999;80(2):125-31
   PubMed Web of Science ®Google Scholar
• Bas E, Van De Water TR, Gupta C, et al. Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. Br J Pharmacol 2012;166(6):1888-904
   PubMedGoogle Scholar
• Park MK, Lee BD, Chae SW, et al. Protective effect of NecroX, a novel necroptosis inhibitor, on gentamicin-induced ototoxicity. Int J Pediatr Otorhinolaryngol 2012;76(9):1265-9
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Eramo SLM, Rolesi R, et al. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32(2):103-10
   PubMed Web of Science ®Google Scholar
• Berkiten G, Salturk Z, Topaloğlu I, Uğraş H. Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats. Am J Otolaryngol 2012;33(6):689-92
   PubMedGoogle Scholar
• Jankauskas SS, Plotnikov EY, Morosanova MA, et al. Mitochondria-targeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss. Biochemistry 2012;77(6):666-70
   PubMedGoogle Scholar
• Chen Y, Huang W-G, Zha D-J, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007;226(1-2):178-82
   PubMed Web of Science ®Google Scholar
• Matz G. Aminoglycoside ototoxicity. Am J Otolaryngol 1986;7(2):117-19
   PubMedGoogle Scholar
• Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man. J Antimicrob Chemother 1984;13(Suppl A):23-30
   PubMedGoogle Scholar
• Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-12
   PubMed Web of Science ®Google Scholar
• Nagai J, Takano M. Review molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004;19(3):159-70
   PubMedGoogle Scholar
• Schreuder MF, Bueters RRG, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatric Nephrol (Berlin, Germany) 2013. [Epub ahead of print]
   Google Scholar
• Allegaert K, Langhendries JP, van den Anker JN. Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 2013;172(4):429-35
   PubMed Web of Science ®Google Scholar
• Provoost A, Adejuyigbe O, Wolff E. Nephrotoxicity of aminoglycosides in young and adult rats. Pediatr Res 1985;19(11):1191-6
   PubMedGoogle Scholar
• Cowan R, Jukkola A, Arant B. Pathophysiologic evidence of gentamicin nephrotoxicity in neonatal puppies. Pediatr Res 1980;14:1204-11
   PubMedGoogle Scholar
• Kunin C, Chesney R, Craig W, et al. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease. Pediatrics 1978;62:751-60
   PubMed Web of Science ®Google Scholar
• Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, et al. Enzymuria determination in children treated with aminoglycosides drugs. Hum Exp Toxicol 2008;27(12):879-82
   PubMedGoogle Scholar
• Zaffanello M, Brugnara M, Bruno C, et al. Renal function and volume of infants born with a very low birth-weight: a preliminary cross-sectional study. Acta Paediatrica (Oslo, Norway: 1992) 2010;99(8):1192-8
   PubMed Web of Science ®Google Scholar
• Giapros VI, Papadimitriou FK, Andronikou SK. Tubular disorders in low birth weight neonates after prolonged antibiotic treatment. Neonatology 2007;91(2):140-4
   PubMedGoogle Scholar
• Giapros VI, Andronikou SK, Cholevas VI, Papadopoulou ZL. Renal function and effect of aminoglycoside therapy during the first ten days of life. Pediatric Nephrol (Berlin Germany) 2003;18(1):46-52
   PubMedGoogle Scholar
• Vieux R, Fresson J, Guillemin F, Hascoet JM. Perinatal drug exposure and renal function in very preterm infants. Archiv Dis Child Fetal Neonatal Ed 2011;96(4):F290-5
   PubMed Web of Science ®Google Scholar
• McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One 2012;7(8):e43809
   PubMed Web of Science ®Google Scholar
• Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatric Nephrol (Berlin, Germany) 2006;21(7):931-8
   PubMed Web of Science ®Google Scholar
• Martínková J, Pokorná P, Záhora J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010;32(14):2400-14
   PubMedGoogle Scholar
• Lundergan FS, Glasscock GF, Kim EH, Ronald S. Once-daily gentamicin dosing in newborn infants. Pediatrics 1999;103:1228-34
   PubMedGoogle Scholar
• Peake M, Whiting M. Measurement of serum creatinine–current status and future goals. Clin Biochem Rev 2006;27(4):173-84
   PubMedGoogle Scholar
• Skopnik H, Troster K, Heimann G, et al. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992;8(67):57-61
   Google Scholar
• Rastogi A, Agarwal G, Pyati S, Pildes RS. Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J 2002;21(3):234-40
   PubMedGoogle Scholar
• De Alba Romero C, Gomez Castillo E, Manzanares Secades C, et al. Once-daily gentamicin dosing in neonates. Pediatr Infect Dis 1998;17:1169
   Google Scholar
• Hayani K, Hatzopoulos F, Frank A, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatrics 1997;131:76-80
   PubMed Web of Science ®Google Scholar
• Tessin I, Bergmark J, Hiesche K, et al. Renal function of neonates during gentamicin treatment. Arch Dis Child 1982;57(10):758-60
   PubMedGoogle Scholar
• Rajchgot P, Prober CG, Soldin S, et al. Aminoglycoside-related nephrotoxicity in the premature newborn. Clin Pharmacol Ther 1984;35(3):394-401
   PubMedGoogle Scholar
• Kotze A, Bartel PR, Sommers DK. Once versus twice daily amikacin in neonates: prospective study on toxicity. J Paediatr Child Health 1999;35(3):283-6
   PubMedGoogle Scholar
• Lietman S, Smith CR, Lipsky JJ, Lietman PS. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. 1979;15(6):780-2
   Google Scholar
• Agarwal G. Original article comparison of once-daily versus twice-daily gentamicin. J Perinatol 2002;22:268-74
   PubMedGoogle Scholar
• Mercado M, Brodsky N, McGuire M, Hurt H. Extended interval dosing of gentamicin in preterm infants. Am J Perinatol 2004;21(2):73-7
   PubMed Web of Science ®Google Scholar
• Isemann B, Kotagal U, Mashni S, et al. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Ther Drug Monit 1996;18(5):549-55
   PubMedGoogle Scholar
• Allen A, Mccracken H, Roeser RJ, Chrane DF. Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up Study. Pediatrics 1979;63:443
   PubMedGoogle Scholar
• Langhendries J, Battisti O, Bertrand J, et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-30
   PubMedGoogle Scholar
• Krishnan L, George S. Gentamicin therapy in preterms: A comparison of two dosage regimens. Indian Pediatrics 1997;34(12):1075-80
   PubMedGoogle Scholar
• Kosalaraka P, Janthep P, Jirapradittha J, et al. Once versus twice daily dose of gentamicin therapy in Thai neonates. J Med Assoc Thailand 2004;87:372-6
   Google Scholar
• Davidović-Plavšić B, Vujić T, Uletilović S, et al. Urinary activities of proximal tubule enzymes in neonates treated with gentamicin. J Med Biochem 2010;29(1):44-7
   Google Scholar
• Abdel-Hady E, El Hamamsy M, Hedaya M, Awad H. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther 2011;36(1):45-52
   PubMedGoogle Scholar